BIO

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories, Inc. (BIO) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (C-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
B+
Factor Score 3.7 / 5.0
Revisions
C-
Factor Score 2.1 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 9.7
EV / EBITDA 23.2
Rev Growth YoY 0.5%
Gross Margin 52.2%
Price Return 3M 3.1%
Price Return 12M 11.9%
Catalyst Signal +0.11
Market Cap $9.9B
TTM Revenue $2.6B
Price / Sales 3.8
ROE 14.3%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (2.9) C- (1.9) B (3.2) B+ (3.7) C- (2.1) C+ (2.8)
2026-11-09 C+ (2.8) C- (1.9) B (3.2) B+ (3.7) C- (2.1) C+ (2.7)
2026-11-06 C+ (2.5) C- (1.9) B (3.2) B+ (3.7) C- (2.1) C+ (2.7)
2026-11-05 C+ (2.5) C- (2.0) B (3.2) B+ (3.6) C (2.3) C+ (2.7)
2026-11-02 C+ (2.5) C- (1.9) B (3.2) B+ (3.5) C- (1.9) C+ (2.6)
Page 1 of 5